BRM (BRM) / FY25

Barramundi NPAT fell 71.9% as an H2 portfolio loss wiped out H1 gains

HY25 already contained 113% of full-year NPAT, implying a loss-making second half even as cash and equity rose.

Release date
18 August 2025
Published
22 April 2026

What changed

Investment income (reported as revenue) fell 62.4% to NZ$12.5m, dragging PBT down 70.8% to NZ$8.5m and NPAT down 71.9% to NZ$7.9m. Operating cash flow swung from a NZ$11.3m inflow to a NZ$0.5m outflow. Despite the P&L weakness, the balance sheet strengthened: cash rose to NZ$22.0m from NZ$5.8m, borrowings remained nil, and total equity increased 11.5% to NZ$240.6m — a NZ$24.8m equity uplift that is materially larger than FY25 NPAT, implying a capital-raising or reinvestment contribution outside reported earnings. The final dividend was cut 7.8% to 1.41cps.

What matters

  • Second half was loss-making. HY25 NPAT was NZ$8.9m, already 113% of the FY25 figure, implying an H2 NPAT of roughly –NZ$1.0m on only NZ$1.2m of H2 revenue (9.4% of the full-year revenue). The full-year headline understates how poor the second half was.
  • Dividend cover deteriorated sharply. Payout against NPAT rose to 56.6% from 15.2%, and ROE fell to 3.3% from 13.0%. The dividend was trimmed, but far less than earnings fell.
  • Cash conversion broke down. Operating cash flow moved NZ$11.8m adversely year-on-year into net outflow territory, even though headline profit was still positive.

Expectations

No stated targets, forward-work book, or guidance were disclosed, and as a listed investment vehicle the result is inherently driven by mark-to-market portfolio movements rather than a repeatable revenue run-rate. The HY25/FY25 shape is the only forward signal available and it is negative: H2 revenue of NZ$1.2m and an H2 NPAT loss mean the exit trajectory into FY26 is materially weaker than the full-year averages suggest.

Quality of result

Earnings quality is low on two fronts. First, the result is tax-distorted — the effective tax rate was 6.6% (FY24: 3.1%), well below a statutory rate, so PBT (–70.8%) is the cleaner read than NPAT (–71.9%). Second, the NZ$7.9m profit was not backed by cash: operating activities produced a NZ$0.5m outflow, versus an NZ$11.3m inflow in FY24, meaning much of the profit is unrealised fair-value movement rather than realised cash income. Balance-sheet direction is the genuinely durable positive: cash quadrupled, gearing remained zero, and equity rose, but much of that appears to reflect capital inflows rather than earnings retention.

Unresolved

  • What drove the H2 reversal — was it specific portfolio holdings, sector exposure, or broader market mark-downs?
  • The NZ$24.8m equity increase exceeds NZ$7.9m NPAT by roughly NZ$17m; the release extract does not make the source (share issuance, DRP, other comprehensive income) explicit.
  • With payout at 56.6% of NPAT and operating cash flow negative, how is the dividend being funded going forward?
  • No capex, free cash flow, NTA per share, or portfolio concentration detail is disclosed in the extracted material.

This briefing cannot assess portfolio composition, underlying holding-level performance, or NTA-to-price valuation, none of which were provided in the extraction.

Key metrics

← Swipe to view more
Metric FY25 FY24 Change
Revenue $12.5m $33.1m -62.4% ↓
Net profit after tax $7911m $28112m -71.9% ↓
Net cash inflow from operating activities −$509m $11298m -104.5% ↓
Final dividend per share 1.4c 1.5c -7.8% ↓
Profit before tax $8465m $29015m -70.8% ↓
Cash and cash equivalents $22.0m $5.8m +280.7% ↑
Total assets $241.7m $218.7m +10.5% ↑

Reference: annolyse.ai/briefings/brm-fy25

Analytical metrics

← Swipe to view more
Metric FY25 FY24 Context
PBT growth -70.8% cleaner earnings measure
Effective tax rate 6.5% 3.1%
Net debt −$22.0m −$5.8m −$16.2m
Gross borrowings $0.0m
Payout ratio vs NPAT 56.6%
ROE (annualised) 3.3% 13.0% Weakening
HY25 share of FY25 revenue 90.6% Other half was 9.4%
HY25 share of FY25 NPAT 113.0% Other half was -13.0%
Profit from continuing operations $7911.0m $28.1m +$7882.9m

Reference: annolyse.ai/briefings/brm-fy25


This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.

Metric context

Trajectory before this result

A compact view of the company's recent revenue and margin path, derived from the same metrics history that powers the company page.

BRM revenue trajectory

Revenue context before the current result.

BRM EBITDA margin

Earnings margin across covered periods.

Appendix

Reference material

Company materials considered in this briefing.

Current period

BRM - Financial statements for the year ended 30 June 2025 incl audit report

FY25 / financial report

BRM - Preliminary year end announcement - 30 June 2025

FY25 / results release

Prior comparable period

BRM - Financial Statements for year ended 30 June 2024 incl audit report

FY24 / financial report

BRM - Preliminary year end announcement - 30 June 2024

FY24 / results release

Interim context

BRM - Interim Financial Statements for period to 31 Dec 2024 including review report

HY25 / financial report

BRM- Preliminary half year announcement - 31 December 2024

HY25 / results release

Email updates

Want briefings like this for the next reporting season?

Get the next Annolyse briefing by email when it is published.